NASDAQ:ATRC AtriCure - ATRC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $44.09 -3.11 (-6.59%) (As of 02/6/2023 04:30 PM ET) Add Compare Share Share Today's Range$44.06▼$47.4150-Day Range$41.37▼$47.2252-Week Range$32.51▼$72.31Volume296,914 shsAverage Volume283,292 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$60.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AtriCure MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.9% Upside$60.67 Price TargetShort InterestHealthy2.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.10) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector415th out of 1,027 stocksSurgical & Medical Instruments Industry43rd out of 105 stocks 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.67, AtriCure has a forecasted upside of 34.9% from its current price of $44.96.Amount of Analyst CoverageAtriCure has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.84% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in AtriCure has recently decreased by 10.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 1.8 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AtriCure this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of AtriCure is held by insiders.Percentage Held by Institutions95.27% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($1.10) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -36.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -36.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AtriCure (NASDAQ:ATRC) StockAtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.Read More Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comStockNews.com Upgrades AtriCure (NASDAQ:ATRC) to HoldJanuary 31, 2023 | finance.yahoo.comAtriCure Announces the First Patient Treated in the LeAAPS™ Clinical TrialFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 30, 2023 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Sees Significant Drop in Short InterestJanuary 24, 2023 | finance.yahoo.comAtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology ConferenceJanuary 9, 2023 | finance.yahoo.comAtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023December 31, 2022 | finance.yahoo.comEstimating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)December 20, 2022 | finance.yahoo.comAtriCure to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 8, 2022 | finance.yahoo.comAtriCure Wins 2022 NACD Diversity, Equity, & Inclusion AwardDecember 4, 2022 | finance.yahoo.comAt US$45.56, Is It Time To Put AtriCure, Inc. (NASDAQ:ATRC) On Your Watch List?November 8, 2022 | finance.yahoo.comAtriCure to Present at 34th Annual Piper Sandler Healthcare ConferenceNovember 1, 2022 | finance.yahoo.comAtriCure Reports Third Quarter 2022 Financial ResultsOctober 19, 2022 | bizjournals.comAtricure remains Cincinnati's best-paying public company - The Business JournalsOctober 14, 2022 | businesswire.comRadiofrequency Based Devices Global Market Report 2022: RF Waves' Applications in Numerous Medical Specialties Driving Growth - ResearchAndMarkets.com - Business WireOctober 11, 2022 | finance.yahoo.comAtriCure to Announce Third Quarter 2022 Financial ResultsOctober 10, 2022 | finance.yahoo.comRadiofrequency Based Devices Global Market to Reach $6.6 Billion by 2027 - Yahoo FinanceOctober 10, 2022 | bizjournals.comStandard Bariatrics $300M sale complete; exit stands among top three largest in Cincinnati region - The Business JournalsOctober 9, 2022 | finance.yahoo.comAtriCure (NASDAQ:ATRC) shareholders have earned a 11% CAGR over the last five years - Yahoo FinanceOctober 9, 2022 | finance.yahoo.comAtriCure (NASDAQ:ATRC) shareholders have earned a 11% CAGR over the last five yearsOctober 6, 2022 | nasdaq.comAtriCure (NASDAQ:ATRC) climbs 5.9% this week, taking five-year gains to 80% - NasdaqSeptember 23, 2022 | nasdaq.comOversold Conditions For AtriCure (ATRC) - NasdaqSeptember 13, 2022 | nasdaq.comNotable Monday Option Activity: ATRC, TXN, RRX - NasdaqSeptember 6, 2022 | businesswire.comAtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders - Business WireSeptember 6, 2022 | finance.yahoo.comAtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion LeadersAugust 30, 2022 | benzinga.comAblation Technology Market Size Worth US$ 18.09 billion to grow at a CAGR of 8.9% from 2022 to 2030| Gro - BenzingaAugust 16, 2022 | benzinga.comAtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Company Calendar Last Earnings11/03/2021Today2/06/2023Next Earnings (Confirmed)2/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees875Year Founded2000Price Target and Rating Average Stock Price Forecast$60.67 High Stock Price Forecast$71.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+37.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$50.20 million Net Margins-17.76% Pretax Margin-17.69% Return on Equity-12.09% Return on Assets-9.46% Debt Debt-to-Equity Ratio0.15 Current Ratio3.69 Quick Ratio2.92 Sales & Book Value Annual Sales$274.33 million Price / Sales7.48 Cash Flow$0.89 per share Price / Cash Flow49.63 Book Value$10.53 per share Price / Book4.19Miscellaneous Outstanding Shares46,510,000Free Float45,206,000Market Cap$2.05 billion OptionableOptionable Beta1.26 Social Links Key ExecutivesMichael H. CarrelPresident, Chief Executive Officer & DirectorDouglas J. SeithChief Operating OfficerAngela L. WirickChief Financial OfficerVinayak DoraiswamyChief Scientific OfficerSalvatore PriviteraChief Technical OfficerKey CompetitorsNuVasiveNASDAQ:NUVAAlphatecNASDAQ:ATECCardiovascular SystemsNASDAQ:CSIIAngioDynamicsNASDAQ:ANGOIntegra LifeSciencesNASDAQ:IARTView All CompetitorsInsiders & InstitutionsEmerald Advisers LLCBought 88,486 shares on 2/3/2023Ownership: 1.112%Emerald Mutual Fund Advisers TrustBought 56,620 shares on 2/3/2023Ownership: 0.872%Larson Financial Group LLCSold 1,764 shares on 2/3/2023Ownership: 0.045%SG Americas Securities LLCSold 3,847 shares on 2/2/2023Ownership: 0.022%ProShare Advisors LLCBought 5,866 shares on 2/2/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ATRC Stock - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $71.00. On average, they expect the company's share price to reach $60.67 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2023? AtriCure's stock was trading at $44.38 at the beginning of the year. Since then, ATRC stock has increased by 6.4% and is now trading at $47.20. View the best growth stocks for 2023 here. Are investors shorting AtriCure? AtriCure saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,290,000 shares, a decline of 10.4% from the December 31st total of 1,440,000 shares. Based on an average trading volume of 269,100 shares, the short-interest ratio is presently 4.8 days. Currently, 2.8% of the shares of the stock are sold short. View AtriCure's Short Interest. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023. View our ATRC earnings forecast. How can I listen to AtriCure's earnings call? AtriCure will be holding an earnings conference call on Tuesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported $2.11 EPS for the quarter, beating the consensus estimate of ($0.28) by $2.39. The medical device company had revenue of $70.46 million for the quarter, compared to analyst estimates of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 12.09% and a negative net margin of 17.76%. During the same quarter in the prior year, the firm posted ($0.11) EPS. What guidance has AtriCure issued on next quarter's earnings? AtriCure updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of -$1.12--$1.10 for the period, compared to the consensus estimate of -$1.10. The company issued revenue guidance of $330.40 million-$330.40 million, compared to the consensus revenue estimate of $330.06 million. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." Who are AtriCure's major shareholders? AtriCure's stock is owned by many different institutional and retail investors. Top institutional investors include Emerald Advisers LLC (1.11%), Emerald Mutual Fund Advisers Trust (0.87%), New York State Common Retirement Fund (0.52%), Peregrine Capital Management LLC (0.34%), Congress Asset Management Co. MA (0.19%) and Oak Ridge Investments LLC (0.13%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $47.20. How much money does AtriCure make? AtriCure (NASDAQ:ATRC) has a market capitalization of $2.20 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis. How many employees does AtriCure have? The company employs 875 workers across the globe. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567. This page (NASDAQ:ATRC) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.